Gerald Schrenk

Title: **Gerald Schrenk: Innovator in Pro-drug PEG Protein Conjugates**

Introduction

Gerald Schrenk is a notable inventor based in Vienna, Austria, recognized for his contributions to the field of biotechnology. With a focus on innovative methodologies for assessing protein activity, Schrenk has made significant strides through his patented work.

Latest Patents

Gerald Schrenk holds a patent for the invention titled "Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation)." This invention encompasses the creation of in vitro assay systems designed to facilitate the release of water-soluble polymers, such as polyethylene glycol (PEG) and polysialic acid (PSA), from proteins that are modified with reversibly-linked polymers. The patent details methods for analyzing polymer release and measuring the subsequent restoration of protein activity. Furthermore, it encompasses techniques for the quality control of these modified proteins.

Career Highlights

Throughout his career, Gerald Schrenk has worked with prominent companies in the biotechnology field, including Baxalta GmbH and Nektar Therapeutics. His experience within these organizations has enabled him to refine his skills and contribute to significant advancements in protein modification technologies.

Collaborations

Schrenk has also collaborated with notable researchers, including Katalin Varadi and Hanspeter Rottensteiner. These partnerships reflect a commitment to advancing the field of biotechnology through shared expertise and innovation.

Conclusion

Gerald Schrenk stands out as an inventor whose work has implications for the quality control and activity measurement of protein conjugates. With a unique patent and substantial collaborative efforts, he continues to contribute to the advancement of biopharmaceutical technologies in Austria and beyond.